ClinicalTrialsFinder
RecruitingNot ApplicableNCT06702566

The Effect of Serum Ferritin in irAE

The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment

1,500 participants

Start Date

Jul 4, 2024

Study Type

INTERVENTIONAL

Conditions

Acute LeukemiaMalignant Solid TumorsImmune-related Adverse EventSerum Ferritin

Summary

This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria19

  • Only patient who meet all the following conditions can be selected for this trial:
  • Patients voluntarily sign informed consent;
  • The age was 18-75 years old, and the gender was not limited;
  • Patients with definitive diagnosis of malignant solid tumor or acute leukemia;
  • Patients enrolled in will be treated with immunotherapy (including immuno- monotherapy，or immuno- plus targeted therapy, or immuno- plus chemotherapy), or targeted therapy (including targeted monotherapy, or targeted plus chemotherapy), or chemotherapy.
  • The Eastern Cooperative Oncology Group (ECOG) scored 0 or 1 or 2 for physical fitness;
  • Sufficient bone marrow reserve at screening, defined as:
  • Neutrophil absolute value (ANC) \> 1.5 × 10\^9/L；
  • Lymphocyte absolute value (ALC) ≥ 0.3 × 10\^9/L；
  • Platelet (PLT) ≥ 100 × 10\^9/L；
  • Hemoglobin (HGB) ≥ 100g / L;
  • The screening has appropriate organ function and meets the following criteria:
  • Aspartate aminotransferase (AST) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);
  • Alanine aminotransferase (ALT) ≤ 2.5 times ULN (due to tumor infiltration ≤ 5 times ULN);
  • Total serum bilirubin ≤ 1.5 times ULN (due to tumor infiltration ≤ 3 times ULN);
  • Serum creatinine (SCR) ≤ 1.5 times ULN, or creatinine clearance rate ≥ 60ml / min;
  • Have the lowest level of lung reserve, defined as ≤ grade 1 dyspnea and oxygen saturation \> 91% in non oxygen breathing state;
  • International normalized ratio (INR) ≤ 1.5 times ULN, and activated partial prothrombin time (APTT) ≤ 1.5 times ULN;
  • The urine pregnancy test of women of childbearing age is negative. Any male and female patient with fertility must agree to use effective contraceptive methods during the whole study and at least 1 year after the study treatment.

Exclusion Criteria23

  • Patient who meet any of the following conditions well excluded in this trial:
  • Active systemic autoimmune disease is known before screening and is under treatment;
  • Those who stopped systemic hormone therapy for less than 2 weeks before enrollment；
  • Those who have received organ / tissue transplantation before screening;
  • Those who meet any of the following conditions during screening:
  • positive for hepatitis B surface antigen (HBsAg) and / or hepatitis B e antigen (HBeAg);
  • hepatitis B e antibody (HBE AB) and / or hepatitis B core antibody (HBC AB) are positive, and the copy number of HBV-DNA is greater than the lower measurable limit;
  • positive for hepatitis C antibody (HCV AB);
  • positive anti Treponema pallidum antibody (TP AB);
  • HIV antibody test positive;
  • the copy number of EBV-DNA and cmv-dna is greater than the lower measurable limit;
  • The heart meets any of the following conditions during screening:
  • left ventricular ejection fraction (LVEF) ≤ 50% (echo);
  • New York Heart Association (NYHA) class III or IV congestive heart failure;
  • hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension that has not been controlled by standard treatment;
  • have had myocardial infarction or cardiac surgery within 12 months before cell transfusion;
  • clinically significant valvular disease.
  • There are clinical emergencies (such as intestinal obstruction or vascular compression) requiring urgent treatment due to tumor body obstruction or compression during screening;
  • Patients with active bleeding during screening;
  • Patients with deep venous thrombosis or pulmonary embolism within 6 months before screening;
  • Those who received live vaccine within 6 weeks before screening;
  • Patients with active infection and need treatment during screening;
  • Poor compliance.

Interventions

DRUGPD-1 and PD-L1 inhibitor

PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab. PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.

DRUGTargeted drugs

Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs

DRUGchemotherapy drugs

Chemotherapy drugs are determined based on the investigator's decision.

Locations(1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06702566

Related Trials

BY002 IIT Study in R/R Acute Leukemia

NCT072707701 location

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

NCT062071232 locations

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT039700963 locations

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

NCT065752961 location

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

NCT074459841 location